Pharmafocus
Pharmaceutical Industry news, analysis and insights
Ionis Pharmaceuticals has announced that it has entered into a new collaboration and licence agreement with Novartis, aiming to discover, develop and commercialise a novel medicine for patients with lipoprotein(a) or lp(a)-driven cardiovascular disease (CVD).
Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for approximately $7.3bn, or $172.50 per share.
Alexion has announced that it has entered a definitive purchase and licence agreement with Pfizer.
Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focusing on the development of new medicines to treat cardiometabolic diseases.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza, has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).